Characteristic | No. of Patients (%) | P-value | |
---|---|---|---|
ALK + c-Met- (n = 101) | ALK + c-Met+ (n = 15) |  | |
Age, years | |||
 Median | 50 | 44 | 0.551 |
 Range | 25–79 | 24–75 |  |
Gender | |||
 Male | 45 (44.6%) | 7(46.7%) | 1.000 |
 Female | 56(55.4%) | 8(53.3%) |  |
ECOG PS | |||
 0–1 | 88(84.9%) | 15(100.0%) | 0.213 |
  ≥ 2 | 13(15.1%) | 0(0.0%) |  |
Smoking status | |||
 Non-smoker | 83(82.2%) | 14(93.3%) | 0.460 |
 Smoker | 18(17.8%) | 1(6.7%) |  |
Histology | |||
 Adenocarcinoma | 98(97.0%) | 14(93.3%) | 0.228 |
 Others | 3(3.0%) | 1(6.7%) |  |
Clinical staging | |||
 IIIB | 5(5.9%) | 0(0.0%) | 1.000 |
 IV | 96(94.1%) | 15(100.0%) |  |
Lines of crizotinib | |||
 1st-line | 52(51.5%) | 7(46.7%) | 0.787 |
 2nd-or further-lines | 49(48.5%) | 8(53.3%) |  |